公开(公告)号：WO1994024296A2

公开(公告)日：1994-10-27

申请号：PCT/CA1994000201

申请日：1994-04-19

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  ZAMB, Timothy ,  LIANG, Xiaoping ,  RABUIK, Lorne, A.

IPC: C12N15/86

CPC classification number: C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K39/265 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N15/85 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16743 ,  C12N2800/60 ,  C12N2830/00 ,  C12N2830/60

Abstract: Vaccines compositions comprising a pharmaceutically acceptable vehicle and a mutant bovine herpesvirus 1 (BHV-1) wherein (i) at least one non-essential gene of wild-type BHV-1 is deleted and optionally replaced with a gene selected from the group consisting of a foreign gene, a gene encoding a BHV-1 immunogen and a mutant analog of a gene encoding a BHV-1 immunogen; and wherein (ii) the replacement gene is optionally under the control of a promoter; and further wherein (iii) at least one essential gene of wild-type BHV-1 is optionally mutated are provided. Vaccines compositions comprising a pharmaceutically acceptable vehicle and a bovine herpesvirus 1 (BHV-1) wherein (i) at least one non-essential gene is deleted or (ii) an essential gene is mutated are also provided. In addition, related vectors, DNA constructs, a diagnostic assay and methods for treating and preventing BHV-1 infection and other bacterial and viral pathogens of cattle are provided.

Abstract translation: 包含药学上可接受的载体和突变体牛疱疹病毒1（BHV-1）的疫苗组合物，其中（i）野生型BHV-1的至少一种非必需基因被缺失，并且任选地被选自以下的基因替换： 外源基因，编码BHV-1免疫原的基因和编码BHV-1免疫原的基因的突变体类似物; 并且其中（ii）所述置换基因任选地在启动子的控制下; 并且其中（iii）提供野生型BHV-1的至少一种必需基因被任选突变。 还提供了包含药学上可接受的载体和牛疱疹病毒1（BHV-1）的疫苗组合物，其中（i）至少一个非必需基因被缺失或（ii）必需基因被突变。 此外，还提供了相关载体，DNA构建体，诊断测定法和用于治疗和预防牛的BHV-1感染和其他细菌和病毒病原体的方法。

公开(公告)号：WO1994006758A1

公开(公告)日：1994-03-31

申请号：PCT/CA1993000386

申请日：1993-09-21

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  DIMMOCK, Jonathan, R.

IPC: C07C281/10

CPC classification number: C07C281/14 ,  A61K31/175 ,  C07C281/10

Abstract: A number of aryl semicarbazones were prepared as candidate anticonvulsants. When administered orally to rats, significant activity was noted in the maximal electroshock (MES) screen and since neurotoxicity was either absent or reduced (as compared to intraperitoneal injection in mice), high protection indices were found in the majority of the compounds. The semicarbazones displayed little or no activity in the subcutaneous pentylenetetrazol screen. These observations support the theory that one large hydrophobic group (in this case the aryl ring) are requirements for protection in the MES screen. In general, the semicarbazones had rapid onsets of action and the most common mechanism of action was interaction with chloride channels. Empirical and semi-empirical conformational calculations indicated that certain molecular fragments and hydrophobicity of these molecules affect bioactivity.

Abstract translation: 制备了许多芳基缩氨基脲作为候选抗惊厥药。 当大鼠口服给药时，在最大电击（MES）屏幕中观察到显着的活性，并且由于神经毒性不存在或减少（与小鼠腹膜内注射相比），在大多数化合物中发现高保护指数。 氨基脲在皮下戊四氮屏幕中显示很少或没有活性。 这些观察结果支持一个大的疏水基团（在这种情况下是芳环）是MES屏幕中的保护要求的理论。 一般来说，缩氨基脲具有快速的作用机制，最常见的作用机制是与氯离子通道相互作用。 经验和半经验构象计算表明某些分子片段和这些分子的疏水性影响生物活性。

公开(公告)号：WO1993023023A1

公开(公告)日：1993-11-25

申请号：PCT/CA1993000198

申请日：1993-05-14

Applicant: UNIVERSITY OF SASKATCHEWAN ,  YU, Peter, H. ,  ZUO, Dong-Mei

Inventor： UNIVERSITY OF SASKATCHEWAN

IPC: A61K31/135

CPC classification number: A61K31/15 ,  A61K31/135 ,  A61K31/175

Abstract: A method for preventing endothelium damage in mammals, particularly for the treatment of cardiovascular disorders associated to diabetes and uraemia. The invention also relates to a method for alleviating pain associated with gout and arthritis in mammals. The method comprises administering to a mammal an effective amount of an SSAO inhibitor to block the formation of formaldehyde in the endothelium or cartilage tissues for the purpose of treating cardiovascular disorders associated to diabetes and uraemia or for alleviating pain associated with gout and arthritis.

Abstract translation: 一种用于预防哺乳动物内皮损伤的方法，特别是用于治疗与糖尿病和尿血症有关的心血管疾病。 本发明还涉及一种减轻与哺乳动物痛风和关节炎有关的疼痛的方法。 该方法包括向哺乳动物施用有效量的SSAO抑制剂，以阻止内皮或软骨组织中的甲醛形成，用于治疗与糖尿病和尿失禁相关的心血管疾病或减轻与痛风和关节炎相关的疼痛。

公开(公告)号：WO1993008290A1

公开(公告)日：1993-04-29

申请号：PCT/CA1992000449

申请日：1992-10-15

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  POTTER, Andrew, A. ,  REDMOND, Mark, J. ,  HUGHES, Huw, P., A.

IPC: C12N15/62

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/0006 ,  A61K47/62 ,  A61K47/646 ,  A61K47/6829 ,  A61K47/6833 ,  A61K2039/6037 ,  C07K5/1019 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/23 ,  C07K14/285 ,  C07K14/655 ,  C07K16/26 ,  C07K2319/00 ,  C12N2720/12322

Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.

Abstract translation: 公开了新的免疫载体系统，编码相同的DNA以及这些系统的使用。 载体体系包括嵌合蛋白，其包含与选定抗原融合的白细胞毒素多肽。 白细胞毒素用于增加融合在其上的抗原的免疫原性。

公开(公告)号：WO1996024675A1

公开(公告)日：1996-08-15

申请号：PCT/CA1996000049

申请日：1996-01-24

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  POTTER, Andrew, A. ,  MANNS, John, G.

IPC: C12N15/62

CPC classification number: C07K5/1024 ,  A61K39/00 ,  A61K39/0006 ,  A61K47/62 ,  A61K47/646 ,  A61K47/6829 ,  A61K47/6833 ,  A61K2039/6037 ,  C07K5/1008 ,  C07K5/1019 ,  C07K5/1021 ,  C07K7/23 ,  C07K14/005 ,  C07K14/285 ,  C07K14/655 ,  C07K16/26 ,  C07K2319/00 ,  C12N2720/12322

Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected GnRH multimer which consists essentially of at least one repeating GnRH decapepetide sequence, or at least one repeating unit of a sequence corresponding to at least one epitope of a selected GnRH molecule. Under the invention, the selected GnRH sequences may all be the same, or may correspond to different derivatives, analogues, variants or epitopes of GnRH so long as the GnRH sequences are capable of eliciting an immune response. The leukotoxin functions to increase the immunogenicity of the GnRH multimer fused thereto.

Abstract translation: 公开了新的免疫载体系统，编码相同的DNA以及这些系统的使用。 载体体系包括嵌合蛋白，其包含与选定的GnRH多聚体融合的白细胞毒素多肽，所述GnRH多聚体基本上由至少一个重复的GnRH脱羧选择素序列组成，或至少一个对应于所选GnRH分子的至少一个表位的序列的重复单元。 根据本发明，所选择的GnRH序列可以全部相同，或者可以对应于GnRH的不同衍生物，类似物，变体或表位，只要GnRH序列能够引发免疫应答即可。 白细胞毒素的作用是增加与其融合的GnRH多聚体的免疫原性。

公开(公告)号：WO1995003787A1

公开(公告)日：1995-02-09

申请号：PCT/CA1994000409

申请日：1994-07-28

Applicant: UNIVERSITY OF SASKATCHEWAN ,  FOLDVARI, Marianna

Inventor： UNIVERSITY OF SASKATCHEWAN

IPC: A61K09/127

CPC classification number: A61K8/14 ,  A61K9/127 ,  A61K9/1277 ,  A61Q19/00

Abstract: A biphasic multilamellar lipid vesicle comprising a plurality of spaced apart lipid bilayers that include a liposome-forming component and optionally a biologically active agent entrapped within the lipid bilayers. The lipid vesicle also comprises peripheral aqueous solution compartments formed between the lipid bilayers and a central lipophilic core compartment substantially at the center of the multilamellar lipid vesicle.

Abstract translation: 包含多个间隔开的脂质双层的双相多层脂质囊泡，其包含脂质体形成成分和任选地包埋在脂质双层内的生物活性剂。 脂质囊泡还包括在脂质双层和基本上在多层脂质囊泡的中心的中心亲脂性核心隔室之间形成的外围水溶液隔室。

公开(公告)号：WO1993011792A1

公开(公告)日：1993-06-24

申请号：PCT/CA1992000537

申请日：1992-12-11

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  BABIUK, Lorne ,  VAN DEN HURK, Sylvia ,  ZAMB, Tim ,  FITZPATRICK, David

IPC: A61K39/265

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/14143 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16771 ,  C12N2710/24143 ,  C12N2830/30 ,  G01N33/6854 ,  G01N2333/03

Abstract: Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination and methods of recombinantly producing the subunit antigens or nucleotide sequences employed in the vaccines. Preferably, the subunit is a truncated BHV-1 gIV antigen.

Abstract translation: 提供了针对牛疱疹病毒1型（BHV-1）的重组亚单位疫苗，以及接种方法和重组产生疫苗中使用的亚基抗原或核苷酸序列的方法。 优选地，亚基是截短的BHV-1 gIV抗原。

公开(公告)号：WO1992007941A1

公开(公告)日：1992-05-14

申请号：PCT/CA1991000376

申请日：1991-10-24

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  REDMOND, Mark, J. ,  IJAZ, Mohammed, Khalid ,  PARKER, Michael, D.

IPC: C12N15/46

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2720/12322 ,  C12N2720/12323 ,  Y10S530/826

Abstract: Assembled viral particles derived from rotavirus proteins are disclosed. The assembled particles include the inner capsid protein, VP6, in combination with either or both of the outer capsid proteins, VP4 and VP7. These assemblies can be used in vaccine compositions for the treatment and prevention of rotaviral disease.

公开(公告)号：WO1990004018A1

公开(公告)日：1990-04-19

申请号：PCT/US1989004452

申请日：1989-10-06

Applicant: UNIVERSITY OF SASKATCHEWAN ,  HEISE-QUALTIERE, Janette

Inventor： UNIVERSITY OF SASKATCHEWAN ,  LAWMAN, Michael, J., P. ,  OHMANN, Helle, Bielefeldt ,  ATTAH-POKU, Samuel, K.

IPC: C12N05/00

CPC classification number: C07K14/53 ,  A61K38/00 ,  A61K2035/124 ,  C07K16/18 ,  C12N5/0647 ,  C12N2502/11 ,  C12N2502/1394

Abstract: The invention derives from the discovery of cells, NA cells, which have properties indicating that they may be pluripotent lymphohematopoietic progenitor cells. These cells, and the stromal cells derived from bone marrow cultures, produce factors which stimulate the growth of primitive cell colonies, as reflected in their stimulation of the growth of colonies of NA cells. These primitive cell colony stimulating factors (PC-CSFs) may be useful in the treatment of disorders which can be alleviated by the proliferation of desired cells. In addition, the NA cells and/or PC-CSFs) may provide an alternative and/or supplementary method to bone marrow transplantation to alleviate hematopoietic disorders.

Abstract translation: 本发明来源于发现具有表明它们可能是多能淋巴造血祖细胞的特性的细胞NA细胞。 这些细胞和源自骨髓培养物的基质细胞产生刺激原始细胞集落生长的因子，这反映在它们刺激NA细胞集落生长中。 这些原始细胞集落刺激因子（PC-CSF）可用于治疗可通过所需细胞增殖而减轻的病症。 此外，NA细胞和/或PC-CSF）可以为骨髓移植提供替代和/或补充方法以减轻造血障碍。

公开(公告)号：WO1998021231A2

公开(公告)日：1998-05-22

申请号：PCT/CA1997000867

申请日：1997-11-14

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  JIANG, Min ,  POTTER, Andrew, A. ,  MACLACHLAN, Philip, Ronald

IPC: C07K14/00

CPC classification number: C07K14/315 ,  A61K39/00

Abstract: The bovine lactoferrin (bLF) binding protein of Streptococcus uberis (S. uberis) is described, as well as the gene encoding the bLF (1bp). LF-binding proteins can be used in vaccine compositions for the prevention and treatment of S. uberis infections, particularly mastitis, as well as in diagnostic methods for determining the presence of S. uberis infections. Also disclosed is a regulatory region adjacent to 1bp, termed mga.

Abstract translation: 描述了乳房链球菌（S.auberis）的牛乳铁蛋白（bLF）结合蛋白，以及编码bLF（1bp）的基因。 LF结合蛋白可用于预防和治疗乳房链球菌感染，特别是乳腺炎的疫苗组合物，以及用于确定乳房链球菌感染存在的诊断方法。 还公开了与1bp相邻的调节区，称为mga。